关联ALDH2 rs671 多态与慢性病发病率在一个基于人口的韩国队列
Hyun Jin Lee1, Jaekyung Noh1, Seunghwan Jeong1
1Division of Nephrology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, 59 Daesagwan-ro, Yongsan-gu, Seoul, 04401, Korea.
Scientific reports
|March 16, 2026
概括
在韩国的一项人口研究中,脱酶2 (ALDH2) rs671基因变异和酒精消费对慢性病 (CKD) 的发病没有显著影响. 这些因素似乎更相关于CKD的进展,而不是启动.
科学领域:
- 遗传学和流行病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心血管疾病研究研究
背景情况:
- 阿尔德脱酶2 (ALDH2) rs671多态性影响阿尔德排毒,并与心血管疾病有关.
- 它与慢性病 (CKD) 发病率的关联在很大程度上仍未被描述.
- 了解CKD病因中的遗传和生活方式因素对于公共卫生至关重要.
研究的目的:
- 调查ALDH2rs671多态和CKD发病率之间的关系.
- 确定饮酒是否会改变ALDH2 rs671与CKD风险之间的关联.
- 探索ALDH2基因型和酒精摄入量在一般人群中CKD发病中的作用.
主要方法:
- 对来自韩国基因组和流行病学研究的5369名韩国成年人的分析,追踪时间长达18年.
- 对ALDH2rs671基因型 (GG与GA/AA) 的评估以及对酒精消费水平的分类.
- 由低EGFR或新发蛋白尿症定义的事件CKD;用于分析的Cox比例危险模型.
主要成果:
- 在平均11.7年的随访期间,共有1396名参与者 (26.0%) 患有CKD.
- 在ALDH2基因型 (GG与GA/AA) 之间没有观察到CKD风险的显著差异.
- 无论何种程度的酒精消费,都与CKD发病率没有显著的关联. 这些发现在各个子组中是一致的.
结论:
- ALDH2 rs671多态性和酒精摄入量对该队列中CKD发病的相关性有限.
- 与ALDH2相关的生物效应可能在已确定的病的进展中起到更重要的作用,而不是其发病.
- 需要进一步的研究来阐明将ALDH2与病进展联系在一起的具体机制.
相关概念视频
01:25Chronic Kidney Disease I: Introduction
971
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
971
01:24Chronic Kidney Disease II: Clinical Manifestations
880
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
880
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
290
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
290
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
452
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
452
01:28Chronic Kidney Disease III: Interprofessional Care
581
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
581
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94